血清YKL-40作为过敏性肺炎预后预测标志物
研究纳入72例过敏性肺炎(HP)患者、100例间质性肺疾病(ILD)对照和60例健康对照,检测基线和随访时血清及BALF中YKL-40水平。基线血清YKL-40在HP患者中高于健康对照但低于其他ILD,BALF中YKL-40在ILD患者中最高。基线血清YKL-40可预测HP疾病进展和死亡。
要点
- 基线血清YKL-40在HP患者中高于健康对照,但低于其他ILD患者。
- HP患者基线血清YKL-40与DLCO相关,并随时间保持相关。
- 血清YKL-40 cut-off 119 ng·mL-1预测疾病进展,150 ng·mL-1与死亡相关。
核心结论
- 血清YKL-40可能作为过敏性肺炎患者的有用预后生物标志物。
研究设计与样本
- 研究纳入72例HP患者、100例ILD对照和60例健康对照,检测基线和随访时血清及BALF中YKL-40水平。
主要发现
- 基线血清YKL-40在HP患者中显著高于健康对照(p<0.001),但低于其他ILD患者。
- HP患者基线BALF中YKL-40水平在ILD患者中最高。
- HP患者基线血清YKL-40与基线DLCO相关(p<0.01),并随时间保持相关(p<0.001)。
- 疾病进展或死亡的HP患者基线YKL-40水平高于稳定存活者(p<0.001)。
- 基线血清YKL-40 cut-off 119 ng·mL-1预测疾病进展(HR 6.567;p<0.001),cut-off 150 ng·mL-1与死亡相关(HR 9.989;p<0.001)。
关键数值与推荐
- 基线血清YKL-40 cut-off 119 ng·mL-1预测HP疾病进展,HR 6.567(p<0.001)。
- 基线血清YKL-40 cut-off 150 ng·mL-1与HP死亡相关,HR 9.989(p<0.001)。
临床怎么用
- 血清YKL-40可作为HP患者预后评估的参考生物标志物,高基线水平提示进展和死亡风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
YKL-40, a chitinase-like protein mainly secreted by macrophages, neutrophils and epithelial cells, is increased in patients with idiopathic interstitial pneumonia and sarcoidosis. We aimed to investigate the role of YKL-40 as a biomarker in hypersensitivity pneumonitis (HP).72 HP patients, 100 interstitial lung disease (ILD) controls and 60 healthy controls were studied. YKL-40 was measured by ELISA in serum and bronchoalveolar lavage fluid (BALF) at baseline and follow-up. The relationship between YKL-40 levels, clinical variables and disease outcome was evaluated.Baseline serum YKL-40 levels were significantly higher in HP patients than in healthy controls (p<0.001), but lower than in patients with other ILDs. Baseline BALF YKL-40 levels in HP patients were the highest among ILD patients. In HP patients, serum YKL-40 correlated with the diffusing capacity of the lung for carbon monoxide at baseline (p<0.01) and over time (p<0.001). HP patients whose disease progressed or who died had higher baseline YKL-40 levels than those who remained stable and survived (p<0.001). At a cut-off of 119 ng·mL-1, the baseline serum YKL-40 level predicted disease progression (hazard ratio 6.567; p<0.001), and at a cut-off of 150 ng·mL-1 was associated with mortality (hazard ratio 9.989; p<0.001).Serum YKL-40 may be a useful prognostic biomarker in HP patients.
引用
- Long X, He X, Ohshimo S, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. Eur Respir J. 2017. PMID: 27836954. doi:10.1183/13993003.01924-2015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。